The event-free survival of childhood acute lymphoblastic leukemia ( ALL ) has been reported to be superior when oral methotrexate ( MTX ) and 6-mercaptopurine ( 6MP ) maintenance therapy ( MT ) is administered in the evening compared to the morning .